...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AGM Voting

What's your plan for a new CEO and board (other than -- anybody would be better)? I'm not exactly thrilled with the current situation but would prefer to wait until they can sell the company.  I'd be happy with $2 US a share.  Some new CEO and board from the outside would likely be most interested in filling their pockets with $$$ and would wipe out current shareholders in an IPO.

Share
New Message
Please login to post a reply